# A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

> **NCT07638683** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma
- AL Amyloidosis

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT07638683
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-22
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638683, "A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*